| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9112041 | Diabetes Research and Clinical Practice | 2005 | 9 Pages |
Abstract
We conclude that the addition of a thiazolinedione to glimepiride treatment in type 2 diabetic subjects with the metabolic syndrome is associated with a slight but significant reduction of PAI-1 value, related to a similar reduction in insulinresistance.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Endocrinology
Authors
Giuseppe Derosa, Arrigo F.G. Cicero, Antonio Gaddi, Pietro D. Ragonesi, Mario N. Piccinni, Elena Fogari, Sibilla Salvadeo, Leonardina Ciccarelli, Roberto Fogari,